Key result
AI advances cardiovascular imaging processing, but clinical risk stratification still requires validation.
Why the study?
The complexity and volume of cardiovascular imaging data increasingly exceed the capacity of conventional interpretation, motivating the exploration of AI and deep learning tools for improved risk stratification and precision phenotyping.
AI and deep learning are maturing for automated processing of cardiovascular imaging, but their advanced applications for risk stratification and precision phenotyping still require real-world validation before routine clinical implementation.
Cardiovascular imaging plays a central role in the diagnosis, risk stratification, and management of cardiovascular disease, yet the complexity and volume of imaging data increasingly exceed the capacity of conventional interpretation. Artificial intelligence (AI) and deep learning offer new tools to extract quantitative, prognostic, and phenotypic information from routine cardiovascular images. This review summarizes the fundamentals of AI and deep learning, including model architectures, training strategies, and their relevance to cardiovascular imaging, followed by a focused discussion of current applications across chest radiography, chest computed tomography, computed tomography angiography/cardiac computed tomography, cardiac magnetic resonance imaging, echocardiography, and nuclear cardiology imaging. Studies were selected with emphasis on original investigations, large cohort analyses, and external validation studies reflecting current applications of AI in cardiovascular risk stratification and precision phenotyping. Across these modalities, AI applications in automated image processing and analysis have become relatively mature. Multiple multicenter and real-world studies have validated their value in improving efficiency and supporting cardiovascular management. Approaches that move beyond conventional human-defined imaging metrics to infer cardiovascular risk and disease phenotype remain at an earlier stage, requiring further standardization, validation, and clinical evaluation. AI is expanding the role of cardiovascular imaging from visual interpretation toward integrated assessment for risk stratification and precision phenotyping, though further work is needed to confirm generalizability and real-world performance before these tools can guide individual patient management.
No takes yet. Share an insight, caveat, or question.
Diao et al. (2026) conducted a review in Cardiovascular disease. Artificial intelligence and deep learning was evaluated. Artificial intelligence and deep learning in cardiovascular imaging have matured for automated processing, but their use for risk stratification and phenotyping requires further clinical validation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: